Inhibitors of vascular calcification as potential therapeutic targets

Raja Rezg1, Fellype C Barreto, Daniela V Barreto

  • 1INSERM ERI-12 (EA 4292), Amiens, France.

Journal of Nephrology
|June 21, 2011
PubMed

Insights

Vascular calcification, common with aging, increases cardiovascular risks. Inhibitory factors in the arterial wall offer potential therapeutic targets for this condition.

Area of Science:

  • Cardiovascular Science
  • Nephrology
  • Endocrinology

Background:

  • Vascular calcification is a prevalent condition, increasing with age and contributing to cardiovascular morbidity and mortality.
  • It is frequently observed in advanced atherosclerosis, and its severity is exacerbated by diabetes mellitus and chronic kidney disease (CKD).
  • Vascular calcification involves both passive and active calcium phosphate deposition in the arterial wall, counteracted by inhibitory factors.

Purpose of the Study:

  • To review the roles of vascular calcification inhibitors.
  • To identify potential therapeutic targets for vascular calcification.

Main Methods:

  • Literature review of vascular calcification inhibitors.
  • Discussion of passive and active calcification processes.
  • Analysis of inhibitory proteins and nonpeptidic factors.

Main Results:

  • Vascular calcification is a complex process involving calcium phosphate deposition.
  • Inhibitory proteins and nonpeptidic factors play a role in preventing calcification.
  • Several inhibitors are identified as potential therapeutic targets.

Conclusions:

  • Understanding vascular calcification inhibitors is crucial for developing new treatments.
  • Targeting these inhibitors may offer a novel therapeutic strategy for managing vascular calcification.
  • Further research into these inhibitors could mitigate cardiovascular risks associated with vascular calcification.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...